USFDA grants EIR to Neuland Labs for Pashamylaram facility

Pharmaceutical company, Neuland Laboratories Ltd, announced that it has received an establishment inspection report (EIR) for its manufacturing facility located at Pashamylaram in Hyderabad.

In a regulatory filing made on Thursday after the market hours, the company informed that it has received the EIR for its Unit 2 Pashamylaram manufacturing facility from United States Food & Drug Administration (USFDA).

Adding to this, the company said that the inspection was conducted from February 3 to 7, 2020 and has now been closed by USFDA.

Headquartered in Hyderabad (Telangana), Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the chemical needs of the pharmaceutical industry.

At the time of market closing on Friday, the stock of Neuland Laboratories Ltd was trading at Rs 427.95, up by 2.52 per cent against its previous close of Rs 417.45. Its 52-week high is recorded at Rs 734.20 while, its 52-week low is Rs 247.30 on BSE.